Gemcitabine/Carboplatin in a Modified 21-Day Administration Schedule for Advanced-Stage Non-Small-Cell Lung Cancer

Abstract

PurposeGemcitabine/carboplatin is active for advanced-stage non-small-cell lung cancer. Although it has a better toxicity profile than gemcitabine/cisplatin, severe thrombocytopenia can be a problem. We conducted a phase II study of gemcitabine/carboplatin on a 21-day schedule with administration of carboplatin delayed until day 8, intending to decrease the severity of thrombocytopenia and evaluate the feasibility and efficacy of this schedule. Patients and MethodsThirty-one patients with stage IIIB or stage IV non-smallcell lung cancer received gemcitabine 1000 mg/m2 on days 1 and 8 and carboplatin at an area under the curve of 5 mg × minute/mL on day 8, every 21 days. ResultsThe response rate was 22.6%, including 1 complete response. The median time to progression was 161 days, and the median survival was 454 days. Grade 3/4 thrombocytopenia, according to the National Cancer Institute Common Toxicity Criteria, version 3.0, was observed in 2 patients (6.5%) in the first 2 cycles. Nonhematologic toxicity included rash, depression, fever, nausea/vomiting and increased hepatic transaminase. The median courses of delivery were 3, and 13 patients (42%) received the first 3 courses without treatment delay. Dose intensity for each drug was 638 mg/m2 per week for gemcitabine and 1.56 mg × minute/mL per week for carboplatin area under the curve, respectively. ConclusionThis study suggests that gemcitabine/carboplatin with a day-8 administration of carboplatin in a 21-day schedule reduces the severity of thrombocytopenia without having a detrimental effect on efficacy.